肿瘤坏死因子-α、白细胞介素-6和空腹血清胰岛素与接受化疗的转移性乳腺癌患者的临床结局相关。

Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.

作者信息

Bozcuk Hakan, Uslu Gülcan, Samur Mustafa, Yildiz Mustafa, Ozben Tomris, Ozdoğan Mustafa, Artaç Mehmet, Altunbaş Hasan, Akan Ilhan, Savaş Burhan

机构信息

Akdeniz University Medical Faculty, Department of Medical Oncology, Dumlupinar Bulvari, 07070 Antalya, Turkey.

出版信息

Cytokine. 2004;27(2-3):58-65. doi: 10.1016/j.cyto.2004.04.002.

DOI:10.1016/j.cyto.2004.04.002

PMID:15242694

Abstract

INTRODUCTION

To assess the relationship of various growth factors and cytokines with the clinical outcome in metastatic breast cancer patients receiving chemotherapy.

METHODS

Consecutive, metastatic breast cancer patients with measurable disease and receiving palliative chemotherapy were prospectively evaluated for the predictors of progression free survival (PFS) and overall survival (OAS) in relation to serum insulin, insulin resistance, interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-alpha).

RESULTS

Estrogen receptor (ER) status, serum IL-6 and serum TNF- were the independent determinants of PFS, with RR=0.28 (0.13-0.60), P=0.001, RR=2.48 (1.24-5.61), P=0.012, and RR=0.48 (0.23-1.01), P=0.053, respectively. The factors related with OAS in the multivariate analysis were histological grade (RR=7.88 (2.33-26.62), P=0.001), ER status (RR=0.18 (0.06-0.57), P=0.003), serum insulin (RR=0.87 (0.77-0.97), P=0.016), and serum IL-6 (RR=5.99 (1.89-18.97), P=0.002).

CONCLUSIONS

We show for the first time that fasting serum insulin and TNF-alpha levels are independent predictors for OAS and PFS, respectively, in metastatic breast cancer patients. In addition, we also confirm that IL-6 is a poor prognosticator in this group. These results suggest that insulin and TNF-alpha are important biomolecules that may be directly involved in vivo in the progression of metastatic breast cancer.

摘要

引言

评估接受化疗的转移性乳腺癌患者中各种生长因子和细胞因子与临床结局的关系。

方法

对连续的、患有可测量疾病且接受姑息化疗的转移性乳腺癌患者进行前瞻性评估，以确定与血清胰岛素、胰岛素抵抗、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）相关的无进展生存期（PFS）和总生存期（OAS）的预测因素。

结果

雌激素受体（ER）状态、血清IL-6和血清TNF分别是PFS的独立决定因素，RR分别为0.28（0.13 - 0.60），P = 0.001；RR为2.48（1.24 - 5.61），P = 0.012；RR为0.48（0.23 - 1.01），P = 0.053。多变量分析中与OAS相关的因素为组织学分级（RR = 7.88（2.33 - 26.62），P = 0.001）、ER状态（RR = 0.18（0.06 - 0.57），P = 0.003）、血清胰岛素（RR = 0.87（0.77 - 0.97），P = 0.016）和血清IL-6（RR = 5.99（1.89 - 18.97），P = 0.002）。